GlassScriptPhysician profile
Howard K Herman
NPI 1053318774
$6,506.28
in general payments reported to CMS, 2019-2025
24 companies · $905 in 2025
The $905 reported for 2025 was more than what 77% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $512 · 2020: $288 · 2021: $587 · 2022: $558 · 2023: $241 · 2024: $3,415 · 2025: $905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,500 · Food and Beverage: $2,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,500.00 |
| Food and Beverage | $2,061.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spirair, INC. | $2,827.14 | 2024-2025 | Septalign |
| Stryker Corporation | $1,217.50 | 2019-2025 | Audion Et Dilation System, 1788, Scopis Ent |
| Aerin Medical INC. | $586.10 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $291.13 | 2021-2025 | Dupixent |
| Genzyme Corporation | $222.21 | 2019-2025 | |
| Optinose US, INC. | $217.17 | 2019-2023 | |
| Inspire Medical Systems, INC. | $206.83 | 2023-2025 | Inspire |
| Intersect Ent, INC. | $186.70 | 2019-2021 | |
| Glaxosmithkline, LLC. | $152.13 | 2021-2025 | Nucala |
| Phathom Pharmaceuticals, INC. | $92.12 | 2025 | Voquezna |
| Kaleo, INC. | $82.77 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $74.54 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $54.32 | 2025 | Neffy |
| Olympus America INC. | $50.33 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $42.80 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $37.19 | 2019 | |
| Amgen INC. | $34.02 | 2025 | Tezspire |
| Resmed Corp | $33.70 | 2024-2025 | |
| Lilly USA, LLC | $27.38 | 2025 | Zepbound |
| Novartis Pharmaceuticals Corporation | $22.03 | 2021 | |
| Medtronic, INC. | $19.25 | 2021 | |
| Baudax Bio INC. | $15.34 | 2022 | |
| Horizon Therapeutics Plc | $13.58 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Herman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.